By the end of the study, there was a highly significant reduction in the scores in both the E-PR-01 high dose [33.65 (14.95)] and low dose [26.38 (13.58)] as compared to the placebo group, which only experienced a minimal decrease [8.30 (17.84)].
← all excerpts
A Randomized Placebo-Controlled Dose-Response Trial of Muvz<sup>™</sup> for Knee and Low-Back Support in Physically Active Adults.
1
—
—